BIOX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 41 of 49 cases where BIOX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +0.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIOX advanced for three days, in 181 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
BIOX moved below its 50-day moving average on September 24, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BIOX crossed bearishly below the 50-day moving average on September 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIOX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for BIOX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.231) is normal, around the industry mean (-0.279). P/E Ratio (-0.275) is within average values for comparable stocks, (8.524). Projected Growth (PEG Ratio) (1.236) is also within normal values, averaging (0.867). Dividend Yield (0.000) settles around the average of (0.125) among similar stocks. BIOX's P/S Ratio (0.103) is slightly lower than the industry average of (1.476).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. BIOX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIOX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.
The RSI Indicator for SMG moved out of oversold territory on October 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 26 of the 34 cases the stock moved higher. This puts the odds of a move higher at 76%.
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on SMG as a result. In 50 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for SMG just turned positive on October 06, 2026. Looking at past instances where SMG's MACD turned positive, the stock continued to rise in 39 of 57 cases over the following month. The odds of a continued upward trend are 68%.
SMG moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where SMG advanced for three days, in 199 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for SMG moved below the 200-day moving average on September 24, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
SMG broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SMG entered a downward trend on October 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: SMG's P/B Ratio (-15.603) is very low in comparison to the industry average of (-0.279). SMG's P/E Ratio (45.105) is considerably higher than the industry average of (8.524). Projected Growth (PEG Ratio) (0.685) is also within normal values, averaging (0.867). Dividend Yield (0.047) settles around the average of (0.125) among similar stocks. P/S Ratio (0.929) is also within normal values, averaging (1.476).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. SMG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SMG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.
BIOX | SMG | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 76 | 35 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 57 Fair valued | 7 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 95 | 98 | |
PRICE GROWTH RATING 1..100 | 89 | 57 | |
P/E GROWTH RATING 1..100 | 17 | 78 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SMG's Valuation (7) in the Chemicals Agricultural industry is somewhat better than the same rating for BIOX (57) in the Financial Conglomerates industry. This means that SMG’s stock grew somewhat faster than BIOX’s over the last 12 months.
SMG's Profit vs Risk Rating (100) in the Chemicals Agricultural industry is in the same range as BIOX (100) in the Financial Conglomerates industry. This means that SMG’s stock grew similarly to BIOX’s over the last 12 months.
BIOX's SMR Rating (95) in the Financial Conglomerates industry is in the same range as SMG (98) in the Chemicals Agricultural industry. This means that BIOX’s stock grew similarly to SMG’s over the last 12 months.
SMG's Price Growth Rating (57) in the Chemicals Agricultural industry is in the same range as BIOX (89) in the Financial Conglomerates industry. This means that SMG’s stock grew similarly to BIOX’s over the last 12 months.
BIOX's P/E Growth Rating (17) in the Financial Conglomerates industry is somewhat better than the same rating for SMG (78) in the Chemicals Agricultural industry. This means that BIOX’s stock grew somewhat faster than SMG’s over the last 12 months.
| BIOX | SMG | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 78% | 2 days ago 76% |
| Stochastic ODDS (%) | 2 days ago 69% | 2 days ago 81% |
| Momentum ODDS (%) | N/A | 2 days ago 65% |
| MACD ODDS (%) | N/A | 2 days ago 68% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 70% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 69% |
| Advances ODDS (%) | 11 days ago 76% | 2 days ago 69% |
| Declines ODDS (%) | 2 days ago 87% | 21 days ago 77% |
| BollingerBands ODDS (%) | 2 days ago 84% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 74% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIOX’s FA Score shows that 1 FA rating(s) are green while SMG’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIOX’s TA Score shows that 4 TA indicator(s) are bullish while SMG’s TA Score has 5 bullish TA indicator(s).
BIOX (@Chemicals: Agricultural) experienced а -18.39% price change this week, while SMG (@Chemicals: Agricultural) price change was +12.49% for the same time period.
The average weekly price growth across all stocks in the @Chemicals: Agricultural industry was -5.23%. For the same industry, the average monthly price growth was -19.73%, and the average quarterly price growth was -17.84%.
BIOX is expected to report earnings on Nov 11, 2026.
SMG is expected to report earnings on Nov 04, 2026.
The agricultural chemicals sector includes companies that produce chemical products for the agricultural industry applications like crop protection, animal health, biotechnology and pharmaceutical-related products. Some of the largest agricultural chemicals producers include Nutrien Ltd., Corteva Inc., and FMC Corporation.
A.I.dvisor tells us that BIOX and UAN have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIOX and UAN's prices will move in lockstep.
| Ticker / NAME | Correlation To BIOX | 1D Price Change % | ||
|---|---|---|---|---|
| BIOX | 100% | -2.74% | ||
| UAN - BIOX | 21% Poorly correlated | +0.14% | ||
| SEED - BIOX | 20% Poorly correlated | +0.49% | ||
| IPI - BIOX | 20% Poorly correlated | -2.13% | ||
| FMC - BIOX | 20% Poorly correlated | -5.27% | ||
| SMG - BIOX | 20% Poorly correlated | +0.13% | ||
More | ||||
A.I.dvisor tells us that SMG and AVD have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SMG and AVD's prices will move in lockstep.
| Ticker / NAME | Correlation To SMG | 1D Price Change % | ||
|---|---|---|---|---|
| SMG | 100% | +0.13% | ||
| AVD - SMG | 23% Poorly correlated | +0.95% | ||
| BIOX - SMG | 20% Poorly correlated | -2.74% | ||
| CTVA - SMG | 20% Poorly correlated | -1.40% | ||
| MOS - SMG | 19% Poorly correlated | -1.01% | ||
| FMC - SMG | 8% Poorly correlated | -5.27% | ||
More | ||||